Antiproliferative activity of mAbs with and without cross-linking
Antiproliferative activity of mAbs . | Rituximab + hL243γ4P . | Rituximab (P) . | hL243γ4P (P) . |
|---|---|---|---|
| Without cross-linking | |||
| Ramos | 18.2 ± 4.9 | –7.9 ± 3.6 (.001) | 10.1 ± 11.9 (.362) |
| FSCCL | 75.9 ± 10.2 | 13.4 ± 12.3 (.003) | 78.9 ± 1.7 (.661) |
| Namalwa | 50.1 ± 1.1 | 13.8 ± 5.6 (.006) | 27.8 ± 3.3 (.004) |
| In the presence of antihuman second antibody | |||
| Ramos | 69.0 ± 7.0 | 50.5 ± 9.4 (.052) | 56.8 ± 0.8 (.007) |
| FSCCL | 94.5 ± 0.9 | 28.1 ± 9.6 (.007) | 94.5 ± 0.8 (.998) |
| Namalwa | 58.1 ± 2.1 | 14.7 ± 7.0 (.005) | 51.5 ± 3.0 (.042) |
Antiproliferative activity of mAbs . | Rituximab + hL243γ4P . | Rituximab (P) . | hL243γ4P (P) . |
|---|---|---|---|
| Without cross-linking | |||
| Ramos | 18.2 ± 4.9 | –7.9 ± 3.6 (.001) | 10.1 ± 11.9 (.362) |
| FSCCL | 75.9 ± 10.2 | 13.4 ± 12.3 (.003) | 78.9 ± 1.7 (.661) |
| Namalwa | 50.1 ± 1.1 | 13.8 ± 5.6 (.006) | 27.8 ± 3.3 (.004) |
| In the presence of antihuman second antibody | |||
| Ramos | 69.0 ± 7.0 | 50.5 ± 9.4 (.052) | 56.8 ± 0.8 (.007) |
| FSCCL | 94.5 ± 0.9 | 28.1 ± 9.6 (.007) | 94.5 ± 0.8 (.998) |
| Namalwa | 58.1 ± 2.1 | 14.7 ± 7.0 (.005) | 51.5 ± 3.0 (.042) |
Numbers represent percent inhibition of 3H-thymidine uptake, and those in parentheses represent P values of the single mAbs compared with the combination of rituximab and hL243γ4P